Search

Your search keyword '"Hatanaka, N."' showing total 317 results
Start Over Author "Hatanaka, N."
317 results on '"Hatanaka, N."'

15. 2320 Efficacy and safety of Trastuzumab in combination with standard S-1 plus CDDP in HER-2 positive advanced gastric cancer; HOG-GC 01, a single-arm phase 2 study

Author

Tanabe, K., primary, Hatanaka, N., additional, Kanazawa, T., additional, Shinozaki, K., additional, Hirabayashi, N., additional, Kanou, M., additional, Fukuda, T., additional, Matsuda, H., additional, Takashima, H., additional, Takahashi, T., additional, Hamada, T., additional, Sakimoto, H., additional, and Ninomiya, M., additional

Published
2015
Full Text
View/download PDF

17. Kinase-Dead Knock-In Mouse Reveals an Essential Role of Kinase Activity of Ca2+/Calmodulin-Dependent Protein Kinase II in Dendritic Spine Enlargement, Long-Term Potentiation, and Learning

Author

Yamagata, Y., primary, Kobayashi, S., additional, Umeda, T., additional, Inoue, A., additional, Sakagami, H., additional, Fukaya, M., additional, Watanabe, M., additional, Hatanaka, N., additional, Totsuka, M., additional, Yagi, T., additional, Obata, K., additional, Imoto, K., additional, Yanagawa, Y., additional, Manabe, T., additional, and Okabe, S., additional

Published
2009
Full Text
View/download PDF

20. Correspondence

Author

Masao Kinoshita, Yasuo Iwasaki, Toyohara S, Nobuo Wakata, Hatanaka N, Segawa F, and Ken Ikeda

Subjects
medicine.medical_specialty, Neurology, business.industry, medicine, Polyradiculoneuropathy, Neurology (clinical), Atopic dermatitis, medicine.disease, business, Dermatology
Published
1998
Full Text
View/download PDF

23. Pulse cyclophosphamide therapy in CIDP

Author

Ikeda, K., primary, Iwasaki, Y., additional, Hatanaka, N., additional, Kinoshita, M., additional, Wakata, N., additional, Good, J. L., additional, Koski, C. L., additional, Mayer, R. F., additional, and Chehrenama, M., additional

Published
1999
Full Text
View/download PDF

32. Improvement of pancreatic islet cell isolation for transplantation.

Author

Matsumoto S, Noguchi H, Naziruddin B, Onaca N, Jackson A, Hatanaka N, Okitsu T, Kobayashi N, Klintmalm G, and Levy M

Abstract

Pancreatic islet transplantation is a promising treatment for diabetes but still faces several challenges. Poor islet isolation efficiency and poor long-term insulin independence are currently two major issues, although donor shortage and the need for immunosuppressants also need to be addressed. We established the Kyoto islet isolation method (KIIM), which has enabled us to isolate and transplant islets even from non-heart-beating donors. KIIM involves 1) cooling the donor pancreas in situ, 2) preserving the ducts with modified Kyoto solution, 3) using a modified two-layer pancreas preservation method, and 4) adjusting the density of the density gradient centrifugation and using an iodixanol-based solution for purification. KIIM has enabled us to transplant 17 islet preparations out of 21 isolations (an 81% success rate). All transplanted islets functioned, and all transplanted patients had improved glycemic control without hypoglycemic unawareness. Recently, we used KIIM for islet isolation from a brain-dead donor at Baylor, which resulted in a very high islet yield (789,984 IE) with high viability (100% by fluorescein diacetate/propidium iodide staining and a stimulation index of 4.7). This preliminary evidence suggests that KIIM may also be promising for islet isolation from brain-dead donors. In addition, to assess engrafted islet mass, we developed a secretory unit of islet transplant objects (SUITO) index: fasting C-peptide (ng/dL)/[fasting blood glucose (mg/dL) - 63] x 1500. This simple index has enabled us to monitor the engrafted islet mass. This index should be useful when deciding whether to perform additional islet transplantations to maintain insulin independence. Poor islet isolation efficacy and poor long-term results could be resolved with ongoing research. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

35. Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust.

Author

Hatanaka, N, Yamazaki, H, Kizu, R, Hayakawa, K, Aoki, Y, Iwanari, M, Nakajima, M, and Yokoi, T

Abstract

We have shown previously that diesel exhaust particle (DEP) extracts (DEPE) and 1-nitropyrene were genotoxically activated by human cytochrome P450 1B1 in SOS/umu assay. In this study, the in vivo induction of P450 family 1 enzymes in rats by exposure to diesel exhaust was investigated with regard to mRNA levels, P450 enzyme content, drug oxidation activities in the microsomes and umu gene expression of typical P450 substrates and DEPE itself catalyzed by the microsomes. Male Fischer 344 rats (4 weeks old) were exposed to 0.3 and 3.0 mg/m(3) DEP for 12 h per day for 4 weeks; the former dose corresponded to the typical daily airborne particle concentration. The levels of mRNA of rat P450 1B1 and P450 1A1 in the lung and liver were significantly increased 1.1-1.4-fold by exposure to 0.3 mg/m(3) DEP. Diesel exhaust particle extracts induced umu gene expression in Salmonella typhimurium TA1535/pSK1002 in the absence of a functional P450 system and were further activated by human recombinant P450 1B1. Using an O-acetyltransferase overexpressing Salmonella strain, genotoxic activation of P450 1B1 marker chemicals (1-nitropyrene, 1-aminopyrene and DEPE) by lung, liver and kidney microsomes was increased 1.7-4.2-, 1.4-1.5- and 1.0-1.3-fold, respectively, by exposure to 0.3 mg/m(3) DEP. Activation of 3-amino-1,4-dimethyl-5H-pyrido [4,3-b]indole (Trp-P-1; marker for P450 1A1) by lung microsomes and the P450 1A2 content in liver microsomes were slightly increased by exposure to 3.0 mg/m(3) DEP. This is the first report to suggest that typical daily contaminant levels (0.3 mg particle/m(3)) of diesel exhaust can induce P450 1B1 in rats and that the induced P450 1B1 may catalyze the genotoxic activation of DEP.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results